Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that has shown promising results in treating metastatic breast cancer and pancreatic cancer [3][4] - Pelareorep works by inducing anti-cancer immune responses and transforming "cold" tumors into "hot" tumors, enhancing the effectiveness of cancer treatments [3] Leadership Change - Matt Coffey, Ph.D., the President and CEO, will not return after a medical leave of absence and has officially stepped down due to ongoing health concerns [1][2] - Wayne Pisano, Chair of the Board of Directors, will serve as Interim CEO while the company initiates a search for a new CEO [2] Clinical Development - Pelareorep has demonstrated synergies with multiple approved oncology treatments and is currently involved in combination clinical trials for solid malignancies [4] - The company is advancing towards registrational studies for pelareorep in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [4]